Deal Team

Corporate
Intellectual Property
Executive Compensation and Benefits
Antitrust
Restructuring and Finance
Tax

Zoetis in the $350 million sale of its medicated feed additive and water soluble products portfolio to Philbro

On April 28, 2024, Zoetis, Inc. (NYSE: ZTS) and Phibro Animal Health (Nasdaq: PAHC) announced that they have entered into a definitive agreement by which Phibro will acquire Zoetis’ medicated feed additive and water soluble products portfolio and related assets for $350 million.  The acquired product portfolio consists of more than 37 product lines that are sold in approximately 80 countries.

Wachtell, Lipton, Rosen & Katz is serving as legal counsel to Zoetis.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.